137 related articles for article (PubMed ID: 21732037)
1. Induction therapy using the MRC UKALLXII/ECOG E2993 protocol in Chinese adults with acute lymphoblastic leukemia.
Wang H; Chen XQ; Geng QR; Liu PP; Lin GN; Xia ZJ; Lu Y
Int J Hematol; 2011 Aug; 94(2):163-168. PubMed ID: 21732037
[TBL] [Abstract][Full Text] [Related]
2. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.
Rowe JM; Buck G; Burnett AK; Chopra R; Wiernik PH; Richards SM; Lazarus HM; Franklin IM; Litzow MR; Ciobanu N; Prentice HG; Durrant J; Tallman MS; Goldstone AH; ;
Blood; 2005 Dec; 106(12):3760-7. PubMed ID: 16105981
[TBL] [Abstract][Full Text] [Related]
3. At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.
Ganzel C; Wang XV; Rowe JM; Richards SM; Buck G; Marks DI; Litzow MR; Paietta EM; Foroni L; Luger SM; Willman CL; Mullighan CG; Roberts KG; Wiernik PH; Douer D; Lazarus HM; Tallman MS; Goldstone AH
Br J Haematol; 2020 Oct; 191(1):37-43. PubMed ID: 32220069
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
Mansour MR; Sulis ML; Duke V; Foroni L; Jenkinson S; Koo K; Allen CG; Gale RE; Buck G; Richards S; Paietta E; Rowe JM; Tallman MS; Goldstone AH; Ferrando AA; Linch DC
J Clin Oncol; 2009 Sep; 27(26):4352-6. PubMed ID: 19635999
[TBL] [Abstract][Full Text] [Related]
5. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials.
Ramanujachar R; Richards S; Hann I; Goldstone A; Mitchell C; Vora A; Rowe J; Webb D
Pediatr Blood Cancer; 2007 Mar; 48(3):254-61. PubMed ID: 16421910
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with acute lymphoblastic leukemia (ALL) following induction therapy with a modified (pulsed dexamethasone rather than continuous prednisone) UKALL XII/ECOG E2993 protocol at Tawam Hospital, United Arab Emirates (UAE).
Hassan IB; Kristensen J; Alizadeh H; Bernsen R
Med Oncol; 2013 Jun; 30(2):519. PubMed ID: 23468219
[TBL] [Abstract][Full Text] [Related]
7. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Faderl S; Kantarjian HM; Thomas DA; Cortes J; Giles F; Pierce S; Albitar M; Estrov Z
Leuk Lymphoma; 2000 Jan; 36(3-4):263-73. PubMed ID: 10674898
[TBL] [Abstract][Full Text] [Related]
8. Outcome of adult acute lymphoblastic leukaemia following induction chemotherapy with modified MRC UKALL XII/ECOG E2993 protocol.
Islam N; Rahman MM; Aziz MA; Begum F; Yunus AB
Bangladesh Med Res Counc Bull; 2012 Aug; 38(2):43-6. PubMed ID: 23227626
[TBL] [Abstract][Full Text] [Related]
9. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.
Fielding AK; Rowe JM; Richards SM; Buck G; Moorman AV; Durrant IJ; Marks DI; McMillan AK; Litzow MR; Lazarus HM; Foroni L; Dewald G; Franklin IM; Luger SM; Paietta E; Wiernik PH; Tallman MS; Goldstone AH
Blood; 2009 May; 113(19):4489-96. PubMed ID: 19244158
[TBL] [Abstract][Full Text] [Related]
10. Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.
Kumar AJ; Gimotty PA; Gelfand JM; Buck G; Rowe JM; Goldstone AH; Fielding A; Marks DI; Litzow M; Paietta E; Lazarus HM; Tallman MS; Luger SM; Loren AW
Am J Hematol; 2016 Nov; 91(11):1107-1112. PubMed ID: 27468137
[TBL] [Abstract][Full Text] [Related]
11. Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.
Hatta Y; Mizuta S; Matsuo K; Ohtake S; Iwanaga M; Sugiura I; Doki N; Kanamori H; Ueda Y; Yoshida C; Dobashi N; Maeda T; Yujiri T; Monma F; Ito Y; Hayakawa F; Takeuchi J; Kiyoi H; Miyazaki Y; Naoe T
Ann Hematol; 2018 Sep; 97(9):1535-1545. PubMed ID: 29694642
[TBL] [Abstract][Full Text] [Related]
12. Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG).
Tanimoto M; Miyawaki S; Ino T; Kyo T; Sakamaki H; Naoe T; Hiraoka A; Asou N; Ohshima T; Tsubaki K; Kuriyama K; Ueda T; Minamil S; Okabe K; Saito H; Murakami H; Hirano M; Dohy H; Onozawa Y; Suzuki H; Ohno R
Int J Hematol; 1998 Dec; 68(4):421-9. PubMed ID: 9885441
[TBL] [Abstract][Full Text] [Related]
13. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.
Larson RA; Dodge RK; Burns CP; Lee EJ; Stone RM; Schulman P; Duggan D; Davey FR; Sobol RE; Frankel SR
Blood; 1995 Apr; 85(8):2025-37. PubMed ID: 7718875
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study.
Li C; Cai X; Chen X; Liang Y; Xia Z; Wang H
Int J Hematol; 2019 Oct; 110(4):458-465. PubMed ID: 31321731
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia].
Zhang YF; Chen ZM; Lou JY; Ni WM; Wang YG; Meng HT; Tong HY; Qian WB; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):814-8. PubMed ID: 22339953
[TBL] [Abstract][Full Text] [Related]
16. Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study.
Jinnai I; Sakura T; Tsuzuki M; Maeda Y; Usui N; Kato M; Okumura H; Kyo T; Ueda Y; Kishimoto Y; Yagasaki F; Tsuboi K; Horiike S; Takeuchi J; Iwanaga M; Miyazaki Y; Miyawaki S; Ohnishi K; Naoe T; Ohno R
Int J Hematol; 2010 Oct; 92(3):490-502. PubMed ID: 20830614
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
[TBL] [Abstract][Full Text] [Related]
18. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).
Goldstone AH; Richards SM; Lazarus HM; Tallman MS; Buck G; Fielding AK; Burnett AK; Chopra R; Wiernik PH; Foroni L; Paietta E; Litzow MR; Marks DI; Durrant J; McMillan A; Franklin IM; Luger S; Ciobanu N; Rowe JM
Blood; 2008 Feb; 111(4):1827-33. PubMed ID: 18048644
[TBL] [Abstract][Full Text] [Related]
19. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
[TBL] [Abstract][Full Text] [Related]
20. Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia study (JACLS) ALL F-protocol.
Suzuki N; Yumura-Yagi K; Yoshida M; Hara J; Nishimura S; Kudoh T; Tawa A; Usami I; Tanizawa A; Hori H; Ito Y; Miyaji R; Oda M; Kato K; Hamamoto K; Osugi Y; Hashii Y; Nakahata T; Horibe K;
Pediatr Blood Cancer; 2010 Jan; 54(1):71-8. PubMed ID: 19813250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
